Close menu




BAYER AG NA O.N.

Photo credits: pixabay.com

Commented by André Will-Laudien on October 21st, 2025 | 07:45 CEST

AI boom and DAX fireworks! Another 100% with NetraMark, Bayer, and Novo Nordisk

  • AI
  • Biotechnology
  • Biotech
  • Pharma

Savvy investors are already taking notice! Artificial intelligence is revolutionizing drug research and radically reducing development costs. Algorithms are discovering molecular patterns that even the most experienced researchers would overlook, thus accelerating the path from laboratory to patient. Whether in oncology, rare diseases, or metabolic disorders, big data-driven models now enable more precise drug predictions and more realistic simulations of clinical outcomes. Those who understand AI can profit handsomely from the next biotech boom. You just have to muster the courage to finally get involved!

Read

Commented by Fabian Lorenz on October 20th, 2025 | 07:15 CEST

Almost 150% upside potential! Plug Power, Bayer, Planethic Group

  • Vegan
  • Food
  • Sustainability
  • Fuelcells
  • Pharma
  • bevtech

Is Planethic Group (formerly Veganz Group) offering the buying opportunity of the fall? Analysts see over 100% upside potential. The recent correction appears exaggerated and could be an attractive entry point. The Company itself reports massive demand. Plug Power shares have performed strongly in recent months. Instead of taking profits, analysts see further upside — although some voices remain cautious, as the Company has promised to reach break-even many times before. And what do analysts say about Bayer? Very little at the moment. Goldman Sachs recommends the stock as a "Buy", but there is potential for a setback with the upcoming Q3 figures.

Read

Commented by Fabian Lorenz on October 13th, 2025 | 07:05 CEST

Winners in the tariff war: Almonty Industries, MP Materials, Bayer

  • Mining
  • Tungsten
  • Defense
  • Lithium
  • Batteries
  • Pharma

Stock market turmoil on Friday: Donald Trump once again threatens to wield the tariff club. This came in response to China's announcement to tighten export controls on rare earths. Yet, there are also winners in the raw materials battle between the two superpowers. In recent months, the US government has invested in companies such as MP Materials, focusing so far on rare earths and lithium. Will tungsten be next? This critical metal has not been mined in the US for a long time, and Almonty would be the logical partner to change that. Notably, while US stocks lost ground, in some cases heavily, on Friday, Almonty shares recovered significantly from their intraday lows.

Read

Commented by Carsten Mainitz on October 9th, 2025 | 07:35 CEST

BioNxt Solutions, Bayer, Evotec – Enormous upside! The interface of biotech and pharmaceuticals!

  • Biotechnology
  • Biotech
  • Pharma

The global rise in lifestyle diseases such as diabetes, obesity, multiple sclerosis (MS), and MASH (metabolic fatty liver disease) is driving enormous growth in the healthcare sector. The market for cancer therapies is also expanding rapidly. Meanwhile, the M&A landscape is developing dynamically: large pharmaceutical companies need to act as patent protections expire, securing their pipeline through acquisitions and partnerships. Areas offering innovative drugs or novel delivery methods are especially attractive. This is where a promising second-tier stock comes into play.

Read

Commented by Armin Schulz on October 7th, 2025 | 07:20 CEST

Cancer research with billion-dollar potential: How Bayer, Vidac Pharma, and BioNTech could come into play

  • Biotechnology
  • Biotech
  • Pharma
  • Innovations
  • Cancer

The oncology market is booming like no other. Driven by technological quantum leaps and, unfortunately, rising case numbers, cancer treatment is becoming a highly lucrative innovation engine. The sector is growing at double-digit rates every year. Experts predict that the global market volume will break the USD 1 trillion mark within the next decade. No wonder, then, that the race for the next therapeutic breakthroughs in personalized medicines and AI-supported active ingredients is heating up. Investors are focusing not only on established players like Bayer, but also on up-and-coming specialists such as Vidac Pharma and mRNA pioneers like BioNTech.

Read

Commented by André Will-Laudien on October 2nd, 2025 | 07:25 CEST

AI fuels cancer research: Bayer, Vidac Pharma, and Pfizer are the next 150% winners

  • AI
  • Biotechnology
  • Biotech
  • Pharma

The stock market remains strong! In addition to the tech and defense boom, the biotech sector has also been catching up in recent days, with the latest news in cancer research bringing the industry back into the spotlight. The key factor here is artificial intelligence, which is revolutionizing cancer research through personalized therapy approaches based on the evaluation of extensive clinical and genetic data. AI models make it possible to predict individual cancer progression better and tailor therapies to individual patients. By analyzing multimodal data, AI systems can more accurately assess the risk of metastasis and thus develop targeted treatment strategies. AI has also improved tumor diagnostics by accurately detecting numerous types of cancer, therefore ensuring a more precise diagnosis.

Read

Commented by Nico Popp on September 23rd, 2025 | 07:10 CEST

The AI doctor in your pocket: PanGenomic Health, Bayer, CVS Health

  • Healthcare
  • healthtech
  • AI
  • Digitization
  • Pharma

Healthcare costs are a pressing political issue worldwide - in Germany, for example, debates are resurfacing over co-payments and the requirement to see a general practitioner first. This drives more people to self-medicate. The situation is even more extreme in the US: without mandatory insurance and facing extremely high healthcare costs, almost 9% of the population is uninsured, and around 33% is underinsured, leading many citizens to turn to alternative solutions. We examine business models related to increasing personal responsibility in healthcare, with a special focus on a smaller-cap stock.

Read

Commented by Armin Schulz on September 10th, 2025 | 07:05 CEST

Oncology boom: How Bayer, Vidac Pharma, and BioNTech could outperform with their full pipelines

  • Biotechnology
  • Biotech
  • Pharma
  • Oncology

The oncology industry is facing an unprecedented wave of growth: the global market is expected to double to over USD 866 billion by 2034. Driven by demographic factors, groundbreaking immunotherapies, and a record number of new drugs, investors are facing a historic window of opportunity. Those who invest in the right innovators with bulging pipelines and disruptive technologies can benefit from this mega-trend wave. This is precisely where the promising strategies of Bayer, Vidac Pharma, and BioNTech come in.

Read

Commented by Stefan Feulner on September 2nd, 2025 | 07:10 CEST

Bayer, BioNxt Solutions, FamiCord AG – Undiscovered gems with strong growth potential

  • Biotechnology
  • Biotech
  • Pharma
  • Medical
  • Technology

While artificial intelligence has been dominating the headlines for months and tech stocks are reaching record valuations, the biotech sector is leading a shadowy existence on the stock markets. Investors are shying away from the often complex and risky business models, with many stocks trading well below their all-time highs. However, while the spotlight is on AI, significant developments are taking place in the background: clinical trials are reaching key milestones, new therapeutic approaches, such as cell and gene therapies, are advancing, and partnerships with big pharma have increased substantially in recent years.

Read

Commented by Fabian Lorenz on August 25th, 2025 | 07:10 CEST

Massive UNDERVALUATION?! Bayer, SFC Energy, Veganz Group

  • Vegan
  • Food
  • Sustainability
  • Pharma
  • renewableenergies
  • Energy

Massive undervaluation of Veganz shares? The transformation from a vegan food supplier to a foodtech company is increasingly taking shape. The first shipment of oat milk, produced using a revolutionary process, is about to be delivered to the US, and analysts see EUR 160 million in revenue potential. The real question is: When will the target price and the share price rise? Bayer shares have risen surprisingly strongly this year. Investors have largely ignored problem areas. But now a rating agency is pointing out the weaknesses, and analysts remain cautious. Investors were bullish on SFC Energy. Then came the forecast adjustment, and the share price plummeted. Now, a multi-million euro order is helping to stabilize the situation.

Read